Skip to main content

Table 1 Factors associated with progression-free interval by univariate and multivariate analysis using Cox models with lasso penalty

From: Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers

Variables

Threshold

Univariate

Multivariate

HR [95 % CI]

p value

Adjusted p value

HR [95 % CI]

Group

BRCA WT HRD-low

-

1

   

BRCA WT HRD-high

-

0.76 [0.27;2.1]

0.59

0.61

0.83 [0.78; 0.87]

BRCA mutated

-

2.56 [1.1;5.93]

0.03

0.05

1.76 [1.72; 1.80]

HRD score

42.00

1.06 [0.48;2.32]

0.89

0.89

 

TAI score

9.00

1.94 [1.21;3.11]

0.01

0.02

1.38 [1.34; 1.42]

LST score

4.00

1.95 [1.21;3.13]

0.01

0.02

1.19 [1.18; 1.20]

LOH score

3.00

1.33 [0.81;2.17]

0.26

0.32

 

Signature 3 proportion

0.30

0.67 [0.27;1.66]

0.38

0.43

 

Cytotoxicity

59.10

0.49 [0.29;0.81]

0.01

0.02

 

Th1

7.96

0.5 [0.29;0.86]

0.01

0.03

 

CTL

265.94

0.44 [0.25;0.76]

0.00

0.02

 

ICK

430.60

0.34 [0.19;0.61]

0.00

0.00

0.48 [0.47; 0.50]

IFNg

2894.00

0.55 [0.34;0.89]

0.01

0.03

0.98 [0.97; 1.00]

CD274 (PD-L1)

17.04

0.69 [0.43;1.1]

0.12

0.18

 

log10 TMB

− 0.12

1.35 [0.83;2.2]

0.22

0.29

 

T cells

4.07

0.51 [0.32;0.81]

0.01

0.02

0.89 [0.88; 0.90]

CD8 T cells

5.09

0.49 [0.3;0.79]

0.00

0.02

 

Cytotoxic lymphocytes

3.73

0.39 [0.23;0.66]

0.00

0.00

0.65 [0.65; 0.65]

NK cells

1.61

0.56 [0.33;0.95]

0.03

0.06

 

B lineage

3.58

0.52 [0.32;0.84]

0.01

0.02

 

Monocytic lineage

7.64

0.83 [0.52;1.33]

0.44

0.47

 

Myeloid dendritic cells

3.89

0.45 [0.28;0.72]

0.00

0.01

0.75 [0.74; 0.76]

Neutrophils

4.94

0.47 [0.29;0.76]

0.00

0.02

0.67 [0.66; 0.69]

Endothelial cells

7.32

0.78 [0.49;1.26]

0.31

0.38

 

Fibroblasts

13.20

1.64 [1.02;2.63]

0.04

0.07

2.35 [2.25; 2.45]

TILS

0.15

0.54 [0.32;0.9]

0.02

0.04

 
  1. HR: Hazard ratio (high vs low level for dichotomized variables), CI: confidence interval, adj p value : adjusted p value, LOH: loss of heterozygosity, TAI: telomeric allelic imbalance, LST: large scale state transition, CTL: cytotoxic T cell lymphocytes, ICK: inhibitory immune checkpoint, IFNg: interferon gamma, TMB: tumor mutational burden, NK: natural killer, TILS: tumor infiltrating lymphocyte signature